NASDAQ: MYGN · Life Sciences · 8 alerts · CIK 899923
Share price
$5.57Close, Nov 16
Market cap
$534M
Shares outstanding
95.92MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Myriad Genetics Inc filings on SEC EDGAR ↗
Myriad Genetics approved one-time retention stock option awards for its executive leadership team, including the CFO, COO, and CSO. The awards are granted under the 2026 Equity Incentive Plan and will vest fully on the third anniversary of the grant date to ensure leadership continuity during operational efficiency initiatives.
Myriad Genetics reported a revenue decline to $202.7 million for the third quarter of 2026, resulting in a net loss of $43.9 million. While the company significantly reduced its nine-month operating loss compared to the prior year—which was impacted by a $316.7 million impairment charge—it continues to face challenges with rising sales and marketing expenses.
Myriad Genetics detected unauthorized access to its IT network on November 2, 2026, leading to a temporary suspension of testing operations and order management systems. The company has engaged external experts to investigate the scope of the breach, including potential access to patient records, though most systems have since returned to normal operations. Management currently believes the incident will not have a material adverse effect on the business.
Myriad Genetics reported Q3 2026 revenue of $202.7 million and raised its full-year revenue guidance mid-point. The company also highlighted a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash to focus on its Cancer Care Continuum and Mental Health segments.
Counterparty
Labcorp
“We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).”
Sam Raha, President and CEO, Myriad Genetics
“The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance.”
Myriad Genetics Divestiture to Laboratory Corporation of America for $210M
Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business, including the Foresight, Prequel, and SneakPeek tests, to Labcorp for $210 million in cash. The divestiture is part of a strategic review to focus on the company's cancer care continuum and is expected to close by early 2027.
Myriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly following his departure on September 21, 2026. Mr. Donnelly will receive a lump sum severance payment of approximately $1.32 million and accelerated vesting of outstanding time-based and performance-based equity awards for a two-year period. The agreement includes customary non-solicitation and non-disparagement covenants and a release of claims against the company.
Myriad Genetics announced that Brian Donnelly has stepped down as Chief Commercial Officer and will depart the company on September 21, 2026. Vishal Sikri, previously Senior Vice President of Product, has been promoted to Executive Vice President, Commercial, to lead the commercial organization. The company also reaffirmed its previously issued full-year 2026 financial guidance.